$9.8 Billion is the total value of Baker Brothers Advisors's 121 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was 15.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PCYC | Sell | Pharmacyclics Inc. | $1,116,140,000 | -1.6% | 9,129,231 | -5.5% | 11.39% | -20.2% |
| INCY | Incyte Corp. | $1,085,359,000 | +49.1% | 14,845,559 | 0.0% | 11.08% | +20.8% | |
| GEVA | Synageva Biopharma Corp. | $989,182,000 | +34.9% | 10,660,432 | 0.0% | 10.10% | +9.3% | |
| SGEN | Buy | Seattle Genetics, Inc. | $895,197,000 | +7.1% | 27,861,720 | +24.0% | 9.14% | -13.2% |
| AVNR | Buy | Avanir Pharmaceuticals | $652,807,000 | +161.1% | 38,513,713 | +83.6% | 6.66% | +111.6% |
| ACAD | Acadia Pharmaceuticals Inc. | $650,286,000 | +28.2% | 20,481,442 | 0.0% | 6.64% | +3.9% | |
| Salix 2.75% 5/15/15conv bonds | $542,741,000 | -26.4% | 219,440,000 | 0.0% | 5.54% | -40.3% | ||
| GHDX | Buy | Genomic Health Inc. | $436,592,000 | +12.9% | 13,656,318 | +0.0% | 4.46% | -8.5% |
| Incyte Corporation Notes 1.25% 11/15/2020 144Aconv bonds | $421,613,000 | +26.2% | 274,500,000 | 0.0% | 4.30% | +2.3% | ||
| Incyte Corporation Notes 0.375% 11/15/2018 144Aconv bonds | $388,039,000 | +25.9% | 259,000,000 | 0.0% | 3.96% | +2.1% | ||
| Incyte Corporation Notes 4.75% 10/1/2015 144Aconv bonds | $336,182,000 | +49.2% | 40,446,000 | 0.0% | 3.43% | +20.9% | ||
| BMRN | Buy | Biomarin Pharmaceuticals | $335,741,000 | +96.3% | 3,713,950 | +56.7% | 3.43% | +59.1% |
| ANAC | Anacor Pharmaceuticals | $135,602,000 | +31.8% | 4,204,702 | 0.0% | 1.38% | +6.8% | |
| BCRX | Biocryst Pharmaceuticals Inc. | $130,278,000 | +24.3% | 10,713,686 | 0.0% | 1.33% | +0.8% | |
| Biomarin Pharmaceuticals Notes 1.875% 4/23/2017conv bonds | $102,104,000 | +25.5% | 22,898,000 | 0.0% | 1.04% | +1.7% | ||
| BLCM | New | Bellicum Pharmaceuticals, Inc. | $98,697,000 | – | 4,283,732 | +100.0% | 1.01% | – |
| Gilead 1.625% 5/1/16conv bonds | $88,977,000 | -11.4% | 21,500,000 | 0.0% | 0.91% | -28.2% | ||
| DYAX | Dyax Corp. | $86,579,000 | +38.9% | 6,157,789 | 0.0% | 0.88% | +12.6% | |
| CERS | Sell | Cerus | $73,025,000 | +52.5% | 11,702,727 | -2.0% | 0.74% | +23.5% |
| SLXP | Buy | Salix Pharmaceuticals | $73,024,000 | +5321.2% | 635,321 | +7269.5% | 0.74% | +4282.4% |
| Buy | Acorda Therapeutics Notes 1.75% 6/15/2021conv bonds | $69,839,000 | +12.6% | 60,900,000 | +1.5% | 0.71% | -8.7% | |
| Medivation 2.625% 4/1/17conv bonds | $67,334,000 | -0.6% | 34,720,000 | 0.0% | 0.69% | -19.5% | ||
| VNDA | Buy | Vanda Pharmaceuticals, Inc. | $64,041,000 | +41.1% | 4,472,153 | +2.3% | 0.65% | +14.3% |
| XOMA | Sell | Xoma Corp. | $60,757,000 | -37.4% | 16,924,013 | -26.6% | 0.62% | -49.3% |
| XNPT | Buy | Xenoport | $60,545,000 | +65.1% | 6,903,628 | +1.3% | 0.62% | +33.8% |
| VSAR | Buy | Versartis Inc. | $51,225,000 | +116.5% | 2,281,744 | +83.1% | 0.52% | +75.5% |
| MRTX | Mirati Therapeutics Inc. | $44,079,000 | +5.8% | 2,380,074 | 0.0% | 0.45% | -14.3% | |
| DBVT | New | DBV Technologies Inc.sponsored adr | $41,201,000 | – | 1,519,229 | +100.0% | 0.42% | – |
| PGNX | Progenics Pharmaceuticals, Inc. | $33,640,000 | +45.7% | 4,449,797 | 0.0% | 0.34% | +17.9% | |
| DSCI | Derma Sciences | $32,931,000 | +11.8% | 3,537,137 | 0.0% | 0.34% | -9.4% | |
| TGTX | TG Therapeutics | $32,477,000 | +48.5% | 2,050,313 | 0.0% | 0.33% | +19.9% | |
| ACOR | Buy | Acorda Therapeutics, Inc. | $30,879,000 | +21.0% | 755,534 | +0.3% | 0.32% | -1.9% |
| Salix 1.5% 3/15/19conv bonds | $27,339,000 | -24.6% | 15,000,000 | 0.0% | 0.28% | -38.8% | ||
| HALO | Halozyme Therapeutics Inc. | $26,790,000 | +6.0% | 2,776,143 | 0.0% | 0.27% | -14.2% | |
| HRTX | Heron Therapeutics, Inc. | $26,234,000 | +20.8% | 2,607,784 | 0.0% | 0.27% | -2.2% | |
| GILD | Gilead Sciences Inc. | $24,141,000 | -11.5% | 256,108 | 0.0% | 0.25% | -28.3% | |
| RPRX | Sell | Repros Therapeutics | $19,940,000 | -27.5% | 2,000,000 | -28.0% | 0.20% | -41.0% |
| CPRX | Catalyst Pharmaceuticals, Inc. | $19,945,000 | -10.5% | 6,715,462 | 0.0% | 0.20% | -27.4% | |
| AGIO | Sell | Agios Pharmaceuticals | $18,307,000 | +75.6% | 163,393 | -3.8% | 0.19% | +42.7% |
| INSM | Insmed Inc. | $17,138,000 | +18.5% | 1,107,850 | 0.0% | 0.18% | -3.8% | |
| OMER | Sell | Omeros Corp. | $16,060,000 | +56.1% | 648,101 | -19.9% | 0.16% | +26.2% |
| Biomarin Pharmaceuticals Notes 0.75% 10/15/2018conv bonds | $14,715,000 | +11.5% | 12,500,000 | 0.0% | 0.15% | -9.6% | ||
| SGMO | Buy | Sangamo Biosciences, Inc. | $14,531,000 | +55.8% | 955,332 | +10.5% | 0.15% | +26.5% |
| BLUE | Bluebird Bio Inc. | $13,758,000 | +155.6% | 150,000 | 0.0% | 0.14% | +105.9% | |
| NBIX | Neurocrine Biosciences, Inc. | $12,390,000 | +42.6% | 554,590 | 0.0% | 0.13% | +15.6% | |
| CLVS | New | Clovis Oncology | $11,347,000 | – | 202,630 | +100.0% | 0.12% | – |
| MGNX | Macrogenics, Inc. | $10,938,000 | +67.8% | 311,891 | 0.0% | 0.11% | +36.6% | |
| KYTH | Sell | Kythera Biopharmaceuticals | $9,927,000 | -2.6% | 286,255 | -8.0% | 0.10% | -21.1% |
| XNCR | Buy | Xencor | $9,486,000 | +87.9% | 591,371 | +9.0% | 0.10% | +51.6% |
| ARWR | Arrowhead Research Corp. | $9,083,000 | -50.0% | 1,230,802 | 0.0% | 0.09% | -59.4% | |
| AQXP | Sell | Aquinox Pharmaceuticals, Inc. | $9,078,000 | +12.5% | 1,210,350 | -0.1% | 0.09% | -8.8% |
| AERI | Aerie Pharmaceuticals | $8,738,000 | +41.1% | 299,356 | 0.0% | 0.09% | +14.1% | |
| PRQR | ProQR Therapeutics NV | $8,668,000 | +26.1% | 400,000 | 0.0% | 0.09% | +1.1% | |
| SNSS | New | Sunesis Pharmaceuticals Inc. | $8,160,000 | – | 3,200,000 | +100.0% | 0.08% | – |
| OSIR | Osiris Therapeutics Inc. | $8,165,000 | +27.0% | 510,606 | 0.0% | 0.08% | +2.5% | |
| LJPC | La Jolla Pharmaceuticals, Inc. | $7,779,000 | +92.0% | 421,631 | 0.0% | 0.08% | +54.9% | |
| TKMR | Tekmira Pharmaceuticals Corp. | $7,335,000 | -28.3% | 484,156 | 0.0% | 0.08% | -41.9% | |
| CLDN | Celladon Corp | $7,324,000 | +86.7% | 375,000 | 0.0% | 0.08% | +53.1% | |
| NVAX | Novavax Inc. | $7,255,000 | +42.2% | 1,223,362 | 0.0% | 0.07% | +15.6% | |
| IDRA | Buy | Idera Pharmaceuticals Inc. | $7,181,000 | +93.7% | 1,628,172 | +0.6% | 0.07% | +55.3% |
| FOMX | Foamix Pharmaceuticals Ltd. | $7,161,000 | +28.6% | 1,021,600 | 0.0% | 0.07% | +4.3% | |
| CMRX | New | Chimerix | $6,941,000 | – | 172,414 | +100.0% | 0.07% | – |
| THLD | Sell | Threshold Pharma | $6,855,000 | -12.0% | 2,155,516 | -0.1% | 0.07% | -28.6% |
| ARRY | Array Biopharma Inc. | $6,782,000 | +32.5% | 1,433,797 | 0.0% | 0.07% | +7.8% | |
| CNCE | Buy | Concert Pharmaceuticals, Inc. | $6,732,000 | +18.3% | 505,418 | +11.9% | 0.07% | -4.2% |
| RARE | Ultragenyx Pharmaceuticals | $6,582,000 | -22.5% | 150,000 | 0.0% | 0.07% | -37.4% | |
| QLTI | QLT Inc. | $6,159,000 | -11.3% | 1,535,863 | 0.0% | 0.06% | -27.6% | |
| ISIS | Isis Pharmaceuticals, Inc. | $5,946,000 | +59.0% | 96,303 | 0.0% | 0.06% | +29.8% | |
| STML | Stemline Therapeutics Inc. | $5,778,000 | +36.9% | 338,671 | 0.0% | 0.06% | +11.3% | |
| ACHN | Achillion | $5,370,000 | +22.7% | 438,337 | 0.0% | 0.06% | 0.0% | |
| INFI | Infinity Pharmaceuticals Inc. | $5,270,000 | +25.9% | 312,025 | 0.0% | 0.05% | +1.9% | |
| IRWD | Ironwood Pharmaceuticals | $5,303,000 | +18.2% | 346,160 | 0.0% | 0.05% | -3.6% | |
| JUNO | New | Juno Therapeutics Inc. | $5,222,000 | – | 100,000 | +100.0% | 0.05% | – |
| MNKKQ | Sell | Mallinckrodt PUB LTD CO | $4,621,000 | -74.6% | 46,666 | -76.9% | 0.05% | -79.5% |
| ALDR | Alder Biopharmaceutical Inc. | $4,461,000 | +129.5% | 153,350 | 0.0% | 0.05% | +91.7% | |
| DSCO | Discovery Laboratories Inc. | $4,236,000 | -37.0% | 3,652,117 | 0.0% | 0.04% | -49.4% | |
| FOLD | Amicus Therapeutics | $4,008,000 | +39.8% | 481,697 | 0.0% | 0.04% | +13.9% | |
| RXDX | Ignyta | $3,911,000 | -15.0% | 571,000 | 0.0% | 0.04% | -31.0% | |
| LGND | Ligand Pharmaceuticals | $3,906,000 | +13.3% | 73,400 | 0.0% | 0.04% | -7.0% | |
| EPZM | Sell | Epizyme Inc. | $3,811,000 | -34.3% | 201,963 | -5.6% | 0.04% | -46.6% |
| ENTA | Enanta Pharmaceuticals | $3,832,000 | +28.5% | 75,357 | 0.0% | 0.04% | +2.6% | |
| CYTR | Cytrx Corp. | $3,699,000 | +7.9% | 1,350,000 | 0.0% | 0.04% | -11.6% | |
| KPTI | Karyopharm Therapeutics | $3,522,000 | +7.1% | 94,095 | 0.0% | 0.04% | -12.2% | |
| New | Neuroderm Ltd. | $3,510,000 | – | 250,000 | +100.0% | 0.04% | – | |
| ZGNX | Zogenix, Inc. | $3,220,000 | +19.1% | 2,350,400 | 0.0% | 0.03% | -2.9% | |
| CLTX | Celsus Therapeuticssponsored adr ne | $3,235,000 | -21.3% | 673,887 | 0.0% | 0.03% | -36.5% | |
| RCPT | Receptos Inc. | $2,928,000 | +97.3% | 23,900 | 0.0% | 0.03% | +57.9% | |
| SGYPQ | Synergy Pharmaceuticals | $2,968,000 | +9.5% | 973,245 | 0.0% | 0.03% | -11.8% | |
| FMI | Buy | Foundation Medicine Inc. | $2,803,000 | +89.1% | 126,147 | +61.4% | 0.03% | +52.6% |
| New | Aptose Biosciences, Inc. | $2,833,000 | – | 479,164 | +100.0% | 0.03% | – | |
| SAGE | Sage Therapeutics Inc. | $2,745,000 | +16.2% | 75,000 | 0.0% | 0.03% | -6.7% | |
| LPCN | Lipocine Inc. | $2,630,000 | -13.9% | 500,000 | 0.0% | 0.03% | -28.9% | |
| AUPH | Aurinia Pharmaceuticals, Inc. | $2,599,000 | +11.1% | 727,669 | 0.0% | 0.03% | -6.9% | |
| MSTX | Buy | Mast Therapeutics, Inc. | $2,674,000 | +60.0% | 4,774,434 | +59.1% | 0.03% | +28.6% |
| New | Protalix Biotherapeutics, Inc. Notes 4.5% 9/15/18conv bonds | $2,645,000 | – | 3,500,000 | +100.0% | 0.03% | – | |
| BDSI | BioDelivery Sciences Intl. Inc. | $2,524,000 | -29.7% | 210,021 | 0.0% | 0.03% | -42.2% | |
| AFMD | Affimed Therapeutics B.V. | $2,480,000 | -1.6% | 400,000 | 0.0% | 0.02% | -21.9% | |
| BOTA | Biota Pharmaceuticals | $2,479,000 | -9.3% | 1,106,910 | 0.0% | 0.02% | -26.5% | |
| OSUR | Orasure Technologies Inc. | $2,379,000 | +40.4% | 234,664 | 0.0% | 0.02% | +14.3% | |
| MRNS | Marinus Pharmaceuticals Inc. | $2,161,000 | +63.3% | 204,476 | 0.0% | 0.02% | +29.4% | |
| DERM | New | Dermira | $1,811,000 | – | 100,000 | +100.0% | 0.02% | – |
| PRTO | New | Proteon Therapeutics, Inc. | $1,798,000 | – | 172,917 | +100.0% | 0.02% | – |
| OPHT | Ophthotech Corp. | $1,650,000 | +15.2% | 36,776 | 0.0% | 0.02% | -5.6% | |
| PTN | New | Palatin Technologies Inc. | $1,497,000 | – | 2,050,000 | +100.0% | 0.02% | – |
| MDWD | Mediwound Ltd. | $1,499,000 | +5.7% | 225,000 | 0.0% | 0.02% | -16.7% | |
| SNTA | Synta Pharmaceuticals | $1,325,000 | -12.0% | 500,000 | 0.0% | 0.01% | -26.3% | |
| AKAOQ | Achaogen Inc. | $1,305,000 | +45.6% | 100,000 | 0.0% | 0.01% | +18.2% | |
| GERN | Geron Corp. | $1,309,000 | +62.6% | 402,629 | 0.0% | 0.01% | +30.0% | |
| TSRO | Tesaro Inc. | $1,161,000 | +38.2% | 31,218 | 0.0% | 0.01% | +9.1% | |
| LOXO | Loxo Oncology Inc. | $1,175,000 | -10.5% | 100,000 | 0.0% | 0.01% | -29.4% | |
| ALNY | Alnylam Pharmaceuticals, Inc. | $1,125,000 | +24.2% | 11,600 | 0.0% | 0.01% | 0.0% | |
| RIGL | Rigel Pharmaceuticals | $1,094,000 | +17.0% | 481,972 | 0.0% | 0.01% | -8.3% | |
| XLRN | Acceleron Pharma Inc. | $1,121,000 | +28.9% | 28,765 | 0.0% | 0.01% | 0.0% | |
| ADHD | New | Alcobra Ltd. | $1,081,000 | – | 289,871 | +100.0% | 0.01% | – |
| ZIOP | Sell | Ziopharm Oncology Inc. | $982,000 | +52.0% | 193,640 | -20.8% | 0.01% | +25.0% |
| FPRX | Five Prime Therapeutics Inc. | $535,000 | +129.6% | 19,823 | 0.0% | 0.01% | +66.7% | |
| QURE | UniQure B.V. | $454,000 | +59.9% | 30,672 | 0.0% | 0.01% | +25.0% | |
| CCXI | Chemocentryx Inc. | $342,000 | +52.0% | 50,000 | 0.0% | 0.00% | 0.0% | |
| CYCCP | Cyclacel Pharmaceuticals Pfd. Conv. Ex 6%pfd conv ex 6% | $82,000 | -20.4% | 13,253 | 0.0% | 0.00% | 0.0% | |
| AST | New | Asterias Biotherapeutics, Inc. | $54,000 | – | 16,775 | +100.0% | 0.00% | – |
| BTXWS | New | Biotime Inc. Rights | $22,000 | – | 20,525 | +100.0% | 0.00% | – |
| AMBI | Exit | Ambit Biosciences Corp. | $0 | – | -1,093,332 | -100.0% | -0.21% | – |
| AVNR | Exit | Avanir Pharmaceuticals Inc_FLEX C @ 1.0 DEC 14call | $0 | – | -9,356,200 | -100.0% | -1.40% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-02-17
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.